Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond
|
Sep 2017
|
Semin Hematol
|
myelodysplastic syndromes (MDS)
|
Increasing the effectiveness of hematopoiesis in myelodysplastic syndromes: erythropoiesis-stimulating agents and transforming growth factor-β superfamily inhibitors
|
Sep 2017
|
Semin Hematol
|
myelodysplastic syndromes (MDS)
|
Characterization of TP53 Mutations in Low-Grade Myelodysplastic Syndromes and Myelodysplastic Syndromes with a Non-Complex Karyotype
|
Sep 2017
|
Eur J Haematol
|
myelodysplastic syndromes (MDS)
|
Persistent elevation of plasma thrombopoietin levels after treatment in severe aplastic anemia
|
Sep 2017
|
Exp Hematol
|
aplastic anemia
|
Persistent elevation of plasma thrombopoietin levels after treatment in severe aplastic anemia
|
Sep 2017
|
Exp Hematol
|
aplastic anemia
|
Hypomethylating agents in myelodysplastic syndromes and population-level outcomes: a changing landscape or a small dent?
|
Sep 2017
|
Leuk Lymphoma
|
myelodysplastic syndromes (MDS)
|
SOHO State of the Art Update and Next Questions: Biology and Treatment of Myelodysplastic Syndromes
|
Oct 2017
|
Clin Lymphoma Myeloma Leuk
|
myelodysplastic syndromes (MDS)
|
Pro-inflammatory proteins S100A9 and TNFα suppress erythropoietin elaboration in myelodysplastic syndromes
|
Oct 2017
|
Haematologica
|
myelodysplastic syndromes (MDS)
|
Relationship between lenalidomide dose modification, duration of therapy, and long-term outcomes in patients with myelodysplastic syndromes
|
Oct 2017
|
Leuk Res
|
myelodysplastic syndromes (MDS)
|
Somatic HLA mutations expose the role of class I–mediated autoimmunity in aplastic anemia and its clonal complications
|
Oct 2017
|
Blood Advances
|
aplastic anemia
|